New analysis shows survival benefit of Novartis’ Kisqali
In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials
Read More
Tag: ribociclib
Novartis’ Kisqali bests AZ’ Faslodex in breast cancer trial
Adding Kisquali to Faslodex resulted in an almost 30% reduction in risk of death compared to Faslodex alone
Read More
Novartis’ Kisqali hits endpoints in Phase III breast cancer trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.
Read More
NICE rejects Lilly’s breast cancer drug Verzenios
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
Read More
Kisqali wins speedy US breast cancer nod
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
Read More
SMC nod for Novartis’ Kisqali, MSD’s Keytruda
The Scottish Medicines Consortium (SMC has published new guidelines approving NHS funding for medicines for breast cancer and Hodgkin’s lymphoma.
Read More
US awards Novartis’ Kisqali ‘Breakthrough’ status
Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
Read More
NICE waves through breast cancer drugs following price deals
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer’s Ibrance and Novartis’ Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Read More
Novartis breast cancer drug Kisqali wins EU approval
Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.
Read More
US nod for Novartis’ breast cancer drug Kisqali
Novartis’ selective cyclin-dependent kinase inhibitor Kisqali has been approved by the US Food and Drug Administration as a treatment for patients with a certain form of breast cancer.
Read More
Novartis’ breast cancer drug ribociclib gets US, EU review
Novartis’ experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) is now under review on both sides of the Atlantic as a potential treatment for breast cancer.
Read More
US breakthrough status for Novartis’ breast cancer drug
Novartis’ experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) has picked up a Breakthrough Therapy designation in the US for the treatment of certain forms of breast cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
